Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma ...
Cancer remains one of the leading causes of morbidity and mortality worldwide. It is estimated that 19.3 million new cancer cases and nearly 10 million cancer-related deaths were reported in 2020 ...
Machine Learning to Predict the Individual Risk of Treatment-Relevant Toxicity for Patients With Breast Cancer Undergoing Neoadjuvant Systemic Treatment We analyzed follow-up CT reports from patients ...
Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer Artificial intelligence (AI) ...
Should Our Patients Go to Disney World? Weighing the Risk of Infection Versus the Benefits of Social Interactions in Our Pediatric Oncology Patients Of the 1,888 patients with PDAC, 1,162 completed ...
Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer ...
Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast Cancer–Associated Germline Pathogenic Variants in Mexico Moderate hypofractionation (MHF) offers ...
Should Our Patients Go to Disney World? Weighing the Risk of Infection Versus the Benefits of Social Interactions in Our Pediatric Oncology Patients The following represents disclosure information ...
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma In this trial, patients with recurrent ...
Many patients with IBC in LMICs are not receiving TMT. Barriers to diagnosis and treatment were at least partially related to limited providers' comfort level and knowledge, suggesting that ...
LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations Among 187 patients identified (median follow-up, 22.4 ...